VCBeat Health Contact Us
Home Hansoh Pharmaceutical (03692.HK) Receives NMPA Approval for Clinical Trials of Novel ADC HS-20110 in Advanced Solid Tumors

Hansoh Pharmaceutical (03692.HK) Receives NMPA Approval for Clinical Trials of Novel ADC HS-20110 in Advanced Solid Tumors

Dec 17, 2024 20:50 CST Updated 20:50
Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Hansoh Pharma (03692) announced that on December 16, 2024, HS-20110, a novel antibody-drug conjugate (ADC) independently developed by the group, received clinical trial approval from the National Medical Products Administration (NMPA) of China. The drug is expected to be tested in clinical trials for advanced solid tumors.